Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
34.26
-0.01 (-0.03%)
At close: Nov 21, 2025, 4:00 PM EST
34.29
+0.03 (0.08%)
After-hours: Nov 21, 2025, 7:59 PM EST
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Viking Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $87.07, which forecasts a 154.14% increase in the stock price over the next year. The lowest target is $30 and the highest is $125.
Price Target: $87.07 (+154.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 6 | 7 | 7 |
| Buy | 6 | 6 | 6 | 4 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 12 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $106 → $107 | Strong Buy | Maintains | $106 → $107 | +212.32% | Nov 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $106 | Strong Buy | Initiates | $106 | +209.40% | Oct 29, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $80 → $75 | Buy | Maintains | $80 → $75 | +118.91% | Oct 24, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $98 → $102 | Buy | Maintains | $98 → $102 | +197.72% | Oct 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +197.72% | Sep 29, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
7.31M
EPS This Year
-2.69
from -1.01
EPS Next Year
-3.69
from -2.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 97.9M | |||
| Avg | n/a | 7.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.34 | -3.02 | |||
| Avg | -2.69 | -3.69 | |||
| Low | -2.81 | -4.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.